Skip to content

Study · In vitro (cells) · 2015

4 results

Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity.

Tabbì G, Magrì A, Giuffrida A, Lanza V, Pappalardo G, Naletova I, Nicoletti VG, Attanasio F, Rizzarelli E

Journal of inorganic biochemistry28 Sept 2014Cited by 14 (Europe PMC)

PMID25310602 (opens in a new tab)DOI10.1016/j.jinorgbio.2014.09.008 (opens in a new tab)PepBankPUB-25310602
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In SHSY5Y neuroblastoma cells, copper-induced cytotoxicity was reduced in the presence of Semax.

    In plain wordsIn cells, Semax reduced the toxic effect of copper on nerve-like cells.

    Peptide
    Semax
    Outcome
    DecreaseCopper-induced cytotoxicity (MTT assay), SHSY5Y
    Study

    n: not reported in source

    SHSY5Y neuroblastoma cell line
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Noteworthy, a reduced copper induced cytotoxicity was observed in the presence of Semax by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay on a SHSY5Y neuroblastoma and RBE4 endothelial cell lines.
  2. 02LabIn vitro (cells)Activity measurement

    In RBE4 endothelial cells, copper-induced cytotoxicity was reduced in the presence of Semax.

    In plain wordsIn cells, Semax reduced the toxic effect of copper on blood-vessel-lining cells.

    Peptide
    Semax
    Outcome
    DecreaseCopper-induced cytotoxicity (MTT assay), RBE4
    Study

    n: not reported in source

    RBE4 endothelial cell line
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Noteworthy, a reduced copper induced cytotoxicity was observed in the presence of Semax by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay on a SHSY5Y neuroblastoma and RBE4 endothelial cell lines.
  3. 03LabIn vitro (cell-free)Mechanism

    In cell-free equilibrium studies, Semax formed three copper(II) complex species.

    In plain wordsIn lab tests, Semax formed three kinds of complexes with copper.

    Peptide
    Semax
    Outcome
    Not applicableCu(II) complex species of Semax
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The equilibrium study clearly demonstrated the presence of three complex species.

Studies that did not test the peptide alone1

In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semax.

  1. 04LabNot a test of Semax aloneIn vitro (cell-free)Mechanism

    In cell-free studies, above pH5 the [CuLH-2]2- species was predominant, with a 4N planar coordination around copper.

    In plain wordsIn lab tests, above pH5 one copper complex of Semax dominated and had a planar nitrogen arrangement around copper.

    Peptide
    Semax
    Outcome
    Not applicableCoordination mode of the [CuLH-2]2- species
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    From pH5 the [CuLH-2]2- species becomes predominant with the donor atoms around copper arranged in a 4N planar coordination mode.

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.